A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
← catalyst calendarNCT06872125 · readout ≤ 224 d
Sponsored by Stoke Therapeutics, Inc (industry) · STOK — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
170estimated
Sites
61
Countries
China, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-04 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dravet Syndrome
Interventions
- Drug: zorevunersen
- Other: Sham Comparator
Primary outcome
what the primary-completion date above is the date OFMeasurement of Seizure Change
measured Week 28
Permalink · STOK's whole pipeline · Catalyst calendar · Every registered study · What changed